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Introduction: The number of LRRK2 allelic variant has been reported more 
than one hundred thirty. Only a few representative allelic variants were 
studied in Korean ethnicity regarding the contribution of each variant to 
Parkinson disease (PD). Due to the ethnicity-specific distribution of variants, 
it is implausible to apply the results of studies conducted in other ethnicity to 
Korean ethnicity. Through sequencing 122 markers of LRRK2 we investigated 
the frequency and the susceptibility to PD of each allelic variant in Korean 
ethnicity. 
Methods: A total of 1069 unrelated subjects consisting of 663 sporadic PD 
patients and 406 healthy controls were included. As we are a participant of 
GEO-PD (the genetic epidemiology of Parkinson’s disease consortium) 
project, 122 markers of LRRK2 were genotyped. Pearson’s chi-squared test 
was used to assess allelic association with PD. Then, we analyzed them 
through logistic regression analysis adjusting for age and sex to ascertain 
which markers modulate the risk of PD and to determine the extent to which 
the markers modulate the risk of PD. 
Results: None of LRRK2 exonic variants showed statistically significant 
association with the risk of PD. Presumptively, LRRK2 p.N551K (rs7308720; 
OR 0.69, 95% CI 0.52-0.92; p=0.012), p.R1398H (rs7133914; OR 0.68, 95% 
CI 0.51-0.91; p=0.009), p.K1423K (rs11175964; OR 0.69, 95% CI 0.52-0.93; 
p=0.014), p.M2397T (rs3761863; OR 0.73, 95% CI 0.56-0.95; p=0.020) 
carriers showed lower risk of PD than non-carriers; LRRK2 p.A419V 
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(rs34594498; OR 2.21, 95% CI 1.11-4.38; p=0.023) carriers presented higher 
risk of PD than non-carriers using dominant model-based logistic regression 
analysis. In linkage disequilibrium analysis, p.N551K, p.R1398H, p.K1423K 
were in strong LD together (r2>0.8). 
Conclusions: In Korean population, presumptively, p.R1398H, p.N551K, 
p.K1423K variants constituting a haplotype modulate the risk of PD favorably, 
whereas p.A419V is associated with increased risk of PD. Although this result 
did not show statistically significant association, further study with sufficient 
number of subjects can confirm the result of this study. 
 
------------------------------------- 
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Figure 1. Linkage disequilibrium (LD) plot involving 23 markers of 








Parkinson disease (PD) has traditionally been considered a sporadic, 
neurodegenerative disorder. Nevertheless, PD is a heterogeneous, 
multifactorial syndrome with age-associated penetrance for which genetic 
susceptibility contributes to risk (1, 2). In the last 10 years, several 
chromosomal loci (termed PARK), genes, and mutations have been linked to 
familial parkinsonism through classic linkage approaches. In 2002, genetic 
linkage analysis of a Japanese family with dominantly inherited parkinsonism 
reminiscent of L-dopa responsive late-onset PD allowed Funayama and 
colleagues to map a novel PARK locus, PARK8, to chromosome 12q12.3 In 
that locus, subsequent studies identified pathogenic amino acid substitutions 
in a novel gene, leucine-rich repeat kinase 2 (LRRK2; Lrrk2). Seven definite 
pathogenic LRRK2 mutations (encoding LRRK2 N1437H, R1441C, R1441G, 
R1441H, Y1699C, G2019S, and I2020T) have been described so far (4).  
LRRK2 gene has been widely investigated due to its role in pathogenesis of 
PD. Mutations in the LRRK2 are now recognized as the most common genetic 
determinant of familial and sporadic PD.5 Various studies reported that 
LRRK2 mutations account for roughly 10% of the familial and 1-5% of 
sporadic PD (6).  
LRRK2 encompasses approximately 144 kilobases with 51 exons encoding a 
2527 amino acid protein, 286 KDa. LRRK2 is a multidomain protein 
containing several protein interaction motifs as well as dual enzymatic 
domains of GTPase and protein kinase activities, including a leucine-rich 
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repeat domain, armadillo and ankyrin repeats, GTPase (Roc), Roc spacer 
(COR), WD40, and a kinase domain (MAPK) toward the C terminal. All are 
potentially associated with protein-protein interactions (1). The alteration of 
the enzymatic activity caused by genetic variants might induce neuronal cell 
toxicity, hence predisposes to PD. 
The number of polymorphic variants of LRRK2 is also considerable, the 
national center of biotechnology information (NCBI) dbSNP build 132 reports 
as many as one hundred thirty allelic variants in LRRK2 as of 2011. Some 
variants such as p.G2019S were designated as pathogenic variants, while 
others are not reported to be clinically relevant (7). The ethnicity-specific 
distribution of pathogenic variants also hinders particular pathogenic LRRK2 
variants from being accepted as a general risk factor of PD, as a number of 
studies found that specific variants affecting the risk of PD in particular ethnic 
groups do not seem to even exist in other ethnicity even among Asian 
populations; several studies with ethnic Chinese subjects reported that LRRK2 
p.G2385R, p.R1628P are associated with increased risk of PD; however, two 
separate studies with Japanese and Korean subjects showed extremely rare 
frequency of subjects carrying LRRK2 p.R1628P variant (8-12). Therefore, it 
is implausible to generalize the clinical impact of polymorphic variants of 
specific ethnicity to other ethnic groups. 
So far, two Korean ethnic studies with regard to the relationship between 
LRRK2 variants and the risk of PD were aimed to evaluate the clinical impact 
of at most one or two targeted SNPs (12, 13). Among a number of 
polymorphic variants of LRRK2, the question as to which variants have 
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impact that might be deleterious or protective on PD has yet to be elucidated 
in Korean population. Thus, with Korean population, we aimed to evaluate the 
effect of polymorphic variants of LRRK2 on the risk of PD through 
sequencing 122 markers in LRRK2. Being a participant of “LRRK2 variants 
and Parkinson’s disease susceptibility” project of the genetic epidemiology of 
Parkinson’s disease consortium (GEO-PD), we obtained gene sequencing data 
by aid of GEO-PD.  
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MATERIALS AND METHODS 
Materials 
The sporadic PD patients were defined as PD diagnosed by use of the UK 
Parkinson’s Disease Society Brain Bank criteria with typical clinical 
symptoms, late onset, and no family history up to third degree relatives. All 
PD patients were personally examined and have been followed regularly by 
senior neurologist (BSJ) at Seoul national university hospital since 1993. The 
healthy controls were either healthy spouses of PD patients or those who 
presented for routine health examinations. All PD patients and controls were 
native Koreans, and none of them were from consanguineous families. The 
patients were screened with SNCA, PARK2, PINK1, DJ-1, SCA2, and 
SCA17, and those who were positive were excluded from the study. 
 A total of 663 PD patients and 406 healthy controls were included in the 
study. All DNA samples from subjects were collected after ethics approval 
had been obtained from Seoul national university hospital Institutional 
Review Board Committee, and were used in accordance with the terms of the 
written informed consent provided by the participants. 
 
Genetic analysis 
As being a participant of GEO-PD project “LRRK2 variants and Parkinson’s 
disease susceptibility,” we sent Korean study population samples to GEO-PD; 
and samples were analyzed by aid of GEO-PD project. GEO-PD study group 
identified LRRK2 exonic variants through searches of available literature up to 
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April 1, 2010, from personal communications with consortium members, and 
from in-house sequencing studies that had identified novel variants 
(Appendix). Genotyping was performed using MassArray iPLEX platform 
(Sequenom, San Diego, CA, USA) at the Mayo Clinic neurogenetics 
laboratory, FL, USA. 
 
Statistical analysis 
The software STATA/SE version 11 (StataCorp. 2009. Stata Statistical 
Software: Release 11. College Station, TX: StataCorp LP.) and HAPLOVIEW 
were used through the analysis (14). The control groups of each marker were 
assessed for departure from Hardy-Weinberg equilibrium. Pearson’s chi-
squared test was used to assess allelic association with PD. Statistical 
significance level of Pearson’s chi-squared test was set at 0.05, so that the 
study sample size (case: 663, control: 406) has at least 90% power to detect 
allelic effect corresponding to odds ratio of 0.67 or 1.5 at minor allele 
frequency (MAF) 20%. Analysis of linkage disequilibrium (LD) was 
performed using HAPLOVIEW. Along with Pearson’s chi-squared test, fixed-
effects logistic regression analysis was also performed to adjust for the effect 
of age and sex. With this regression model, we assumed that allelic effect 
worked as dominant mode of inheritance, namely dominant model 
(homozygote of ancestral allele vs. heterozygote plus homozygote of minor 
allele), because LRRK2 mutations cause an autosomal dominantly inherited 
form of PD and homozygotes for many of the variants are rare. Thereafter, 
with markers selected by aforementioned analysis we performed logistic 
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regression analysis according to additive model that separates the genotypes 
into three groups in order to give weight to the number of variant allele (none, 
one variant allele, and two variant alleles). 
We adjusted for multiple testing by use of Bonferroni correction according 






A total of 122 markers in LRRK2 were genotyped in the study group 
consisting of 663 unrelated PD patients and 406 healthy controls. The mean 
ages of case (64.5 ± 9.2) and control (63.2 ± 9.1) were different using 
Student’s t-test at significance level, 0.05 (p=0.031); however, the extent of 
difference was clinically negligible, and the difference of sex proportion 
between groups was not significant (Table 1).  
Among 122 markers, ninety-seven markers were monomorphic across all 
1069 subjects. Table 2 summarizes the remaining twenty-five markers which 
are polymorphic and their characteristics. The polymorphic markers, all of 
which are in Hardy-Weinberg equilibrium, were subject to further analyses.  
We adjusted for multiple testing by use of Bonferroni correction to assess the 
level of significance that controls the family-wise error rate at 0.05. After this 
adjustment, p=0.002 was judged to be significant for the number of 
polymorphic variants were twenty-five. Firstly, to examine the difference 
between the allelic frequencies of case and control group, we conducted chi-
squared test with each of the twenty-five markers. All of 25 markers were 
statistically non-significant with significance level 0.002. However, 
presumptive seven markers based on p-value (p.A419V, p=0.010; p.N551K, 
p=0.012; p.R1398H, p=0.013; p.K1423K, p=0.020; p.L1653L, p=0.020, 
p.G2385R, p=0.057; p.M2397T, p=0.054) were selected for further analysis. 
With these seven markers, genotypes were dichotomized as presence versus 
absence of the minor allele (dominant model). Using logistic regression 
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analysis adjusting for age and sex, we obtained odds ratios (OR). From the 
dominant model we assumed, the OR also proved to be non-significant in all 
markers with significance level 0.002 (p.A419V (OR 2.24, 95% CI 1.13-4.46; 
p=0.021), p.N551K (OR 0.69, 95% CI 0.52-0.92; p=0.012), p.R1398H (OR 
0.68, 95% CI 0.51-0.91; p=0.010), p.K1423K (OR 0.69, 95% CI 0.52-0.93; 
p=0.015), p.L1653L (OR 0.19, 95% CI 0.04-0.90; p=0.037), p.M2397T (OR 
0.72, 95% CI 0.55-0.94; p=0.014); p.G2385R (OR 1.63, 95% CI 0.95-2.79; 
p=0.073)). Further analysis was performed with the above seven polymorphic 
markers based on additive model (Table 3). In linkage disequilibrium (LD) 
analysis, among seven markers, p.N551K, p.R1398H, p.K1423K were in 
strong LD together (r2>0.8) (Figure 1). Therefore, these three exonic variants 






Table 1. Study characteristics of cases and controls 
 
 
Age difference between two groups was significant with Student’s t-test 





Table 2. Twenty-five LRRK2 polymorphic variants in study population. 
 
 
Among 25 polymorphic variants, none of them was significant with 
significance level 0.002. However, LRRK2 p.A419V, p.N551K, p.R1398H, 




Table 3. Seven polymorphic variants assorted from twenty-five polymorphic 
variants through chi-squared test. 
 
 
Comparing the OR (odds ratio) and p-values of dominant model to that of 
additive model, they are very similar with each other. All the presented ORs 







Linkage disequilibrium (LD) plot involving 23 markers of LRRK2. The 
numbers of the entries indicate r2 between two corresponding markers. 
(R1398H-N551K: D´=0.94, r2 =0.835; R1398H-K1423K: D´=1.0, r2=0.995; 
N551K-K1423K: D´=0.931, r2 =0.825). The markers of which MAF was less 




We analyzed as many as 122 LRRK2 exonic variants in Korean ethnicity, 
which is the largest genetic association study with LRRK2 and PD so far. The 
result revealed that a single gene, LRRK2, harbors many rare and common 
exonic variants that allow variable susceptibility to PD in Korean ethnicity. 
Although there was no statistically significant association between LRRK2 
exonic variants with PD with this Korean study population, we found a clue 
that p.A419V is hazardous, and a three-variant haplotype (p.N551K-
p.R1398H-p.K1423K) is protective for PD. 
The statistical analysis procedure was based on dominant model, which 
designates heterozygote or minor allele homozygote as a carrier. Taking the 
gene dosage effect into account, additive model is more plausible with regard 
to explaining the causal relationship between allelic variants and phenotype, 
herein PD. Hence analyses based on additive model were conducted with 
seven variant markers.  
The Chinese ethnic study reported that p.A419V was not relevant to the risk 
modulation, however in this study with Korean ethnicity, p.A419V was 
associated with increased risk of PD (15). Although the minor allele 
frequency of case and control was relatively low (0.032, 0.014), the statistical 
significance was consistent through the analyses including dominant and 
additive model. 
We found that the LRRK2 p.R1398H was associated with lower risk of PD 
than was wild type. The recent study with Chinese ethnicity showed that 
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p.R1398H had decreased kinase activity compared to wild type in in-vitro 
experiment (10). In that study, p.R1398H showed decreased risk (OR 0.75), 
which is similar to our result. This protective effect was also shown in 
p.N551K and p.K1423K by similar effect size. Interestingly, all these three 
exonic variants were in strong LD allowing them to be called a haplotype. 
Among the three-variant haplotype (p.N551K-p.R1398H-p.K1423K), which 
one has the main protective function is not clear. The p.N551K is located in 
armadillo repeat region which may participate in signaling complex, and 
p.K1423K is synonymous mutation, but it can lead to alternative splicing and 
different copy number of protein using different tRNA; therefore, the 
characteristic of the protective effect of this haplotype needs further 
investigation. 
Several Asian, especially Chinese-population based studies have reported 
that p.G2385R and p.R1628P variants are associated with approximately 
twofold increase of risk independently. These two exonic variants were not 
found to be a risk factor in the study of European-population based researches 
(9, 15-18). However, p.G2385R was also reported to increase risk for PD in 
Korean and Japanese populations; whereas p.R1628P was absent or extremely 
rare in these populations (11-13). Recently, comprehensive genetic studies of 
LRRK2 in respect to susceptibility to PD were performed in Han Chinese and 
Japanese populations. Except for p.G2385R, the frequencies of polymorphic 
variants were strikingly different between the two populations, and also varied 
from that of our study (Table 4). The p.G2385R was found to increase the risk 
of PD (OR 1.63), but not statistically significant (p=0.073). The minor allele 
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frequency of p.G2385R was very similar to the result of other Korean and 
Han Chinese study, in which minor allele frequency of patients and controls 
were 4.6%, 2.5% and 5%, 2%, respectively; those of our study population 
were 4.1% and 2.5% (12). The lack of significance is presumed to be led by 
insufficient number of subjects of our study population.  
If p.R1398H reduces the risk of PD, the subjects with p.G2385R will differ in 
the risk of PD depending on whether the subjects also have p.R1398H or not, 
taking that the LD between p.G2385R and p.R1938H was negligible into 
account. Although our samples did not present significant result of p.G2385R, 
subjects with both p.G2385R and p.R1398H showed lower OR than those 
with p.G2385R but not p.R1398H (subjects with p.G2385R and p.R1398H: 
OR 0.94, 95% CI 0.15-5.68; p=0.944; subjects with only p.G2385R: OR 1.55, 
95% CI 0.88-2.74; p=0.127). 
The p.G2019S was absent in our study population. The p.R1628P and the 
p.R1441H were extremely rare (MAF < 0.01) as with the result of Japanese 
population study (11). The influence of p.L1653L to the risk of PD is 
questionable due to the scarcity of minor allele frequency in both control and 
case group allowing for the number of subjects included in each group. For 
our study sample sizes and proportions of minor allele, the normal 
approximation to the binomial distribution may not be accurate, thus the result 
of statistical test may not be reliable. Regarding the p.L1653L, due to the 
extremely rare frequency of minor allele, it is hard to confer clinical meaning 
on this variant. The p.M2397T showed confusing result, which was not 
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significant in additive model, which might be caused by relatively low 
frequency of homozygote of minor allele. 
In conclusion, we found a propensity that p.N551K, p.R1398H, p.K1423K 
variants constituting a haplotype may reduce the risk of PD, and the p.A419V 
may be a risk factor of PD in Korean ethnicity. Although the p.G2385R 
represented a risk factor of PD in previous reports, statistical significance was 
not validated in this study maybe due to the insufficient number of study 
subjects. A lack of number of study subjects was the main cause of negative 
results of this study. Therefore, further study that encompasses sufficient 




Table 4. Comparison of LRRK2 polymorphic variants among Asian ethnic 
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dDNA Aminoacid Domain 
1 ··  28G>A E10K ··  
1 rs2256408 149G>A R50H ··  
2 rs72546335 155C>T S52F ··  
2 rs75054132 224G>A A75A ··  
4 rs33995463 356T>C L119P ··  
4 rs41286468 364T>C L122L ··  
5 rs10878245 457T>C L153L ··  
5 rs35517158 546A>G K182K ··  
6 rs112794616 632C>T A211V ··  
6 rs56108242 683G>C C228S ··  
7 rs28365216 713A>T N238I ··  
7 rs72546315 824C>T H275H ··  
8 rs17490713 867T>C N289N ··  
8 rs57355477 893T>C A298A ··  
8 rs41286466 936G>T A312A ··  
9 rs78501232 1000G>A E334K ··  
9 rs36016791 1055delC A352fsX357 ··  
9 rs72546336 1088A>G N363S ··  
9 rs113065049 1096G>A V366M ··  
11 rs34594498 1256C>T A419V ··  
12 rs35847451 1383C>T S461S ··  
13 rs75711334 1464A>T L488L ··  
13 rs34090008 1543insG  P514fsX529 ··  
14 rs35328937 1561A>G R521G ··  
14 rs79996249 1630A>G K544E ··  
14 rs7308720 1653C>G N551K ··  
15 rs77424631 1647G>A G558G ··  
17 rs78154388 1987T>C S663P ··  
17 rs72546319 2022A>C V674V ··  
17 rs35611877 2198insA L708fsX718  Ankyrin 
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18 ··  2134A>G  M712V Ankyrin 
18 ··  2147C>T  A716V Ankyrin 
18 rs10878307 2167A>G I723V  Ankyrin 
19 rs34410987 2264C>T P755L  Ankyrin 
19 rs72546337 2428A>G I810V  Ankyrin 
19 rs76890302 2481T>C S827S  Ankyrin 
20 ··  2611A>G  K871E ··  
21 rs58559150 2769G>C Q923H ··  
21 ··  2789A>G  Q930R ··  
22 rs17519916 2830G>T D944Y ··  
22 rs7966550 2857T>C L953L ··  
23 rs75148313 2918G>A S973N ··  
23 rs113217062 3018A>G I1006M LRR 
23 rs55783828 3021C>T S1007S LRR 
24 rs111341148 3200G>A R1067Q LRR 
24 rs76535406 3287C>G S1096C LRR 
24 rs78365431 3333G>T Q1111H LRR 
24 rs35808389 3342A>G L1114L LRR 
25 rs34805604 3364A>G I1122V LRR 
25 rs74985840 3451G>A A1151T LRR 
25 ·· 3494T>C L1165P LRR 
26 ·· 3574A>G I1192V LRR 
27 rs72546324 3647A>G H1216R LRR 
27 rs80179604 3683G>C S1228T LRR 
27 rs60185966 3683G>T S1228I LRR 
28 rs4640000 3784C>G P1262A LRR 
29 rs77018758 3960G>C/T R1320S ·· 
29 rs72546338 3974G>A R1325Q ·· 
29 rs17466213 4111A>G I1371V Roc 
29 rs28365226 4125C>A D1375E Roc 
30 rs7133914 4193G>A R1398H Roc 
30 rs72546327 4229C>T T1410M Roc 
30 rs113589830 4258G>A D1420N Roc 
30 rs11175964 4269G>A K1423K Roc 
30 rs111435410 4290C>T A1430A Roc 
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30 rs74163686 4309A>C N1437H Roc 
31 rs33939927 4321C>T R1441C Roc 
31 rs33939927 4321C>G R1441G Roc 
31 rs34995376 4322G>A R1441H Roc 
31 rs112998035 4323C>T R1441R Roc 
31 ·· 4324G>C A1442P Roc 
31 rs74681492 4337C>T P1446L Roc 
31 rs111501952 4348G>A V1450I Roc 
31 rs35363614 4387insA R1462fsX1468 Roc 
31 ·· 4402A>G K1468E Roc 
31 rs113431708 4448G>A R1483Q Roc 
32 rs35507033 4541G>A R1514Q COR 
32 rs33958906 4624C>T P1542S COR 
32 rs17491187 4666C>A L1556I COR 
33 rs721710 4793T>A V1598E COR 
34 ·· 4838T>C V1613A COR 
34 rs1427263 4872C>A G1624G COR 
34 rs33949390 4883G>C R1628P COR 
34 rs11176013 4911A>G K1637K COR 
34 rs35303786 4937T>C M1646T COR 
34 rs11564148 4939T>A S1647T COR 
34 rs111503579 4959A>G L1653L COR 
35 rs35801418 5096A>G Y1699C COR 
35 rs79909111 5163A>G S1721S COR 
36 rs11564176 5173C>T R1725X COR 
36 ·· 5183G>T R1728L COR 
36 rs145364431 5183G>A R1728H COR 
37 rs111910483 5385G>T L1795F COR 
37 rs10878371 5457T>C G1819G COR 
38 ·· 5605A>G M1869V COR 
38 rs35602796 5606T>C M1869T COR 
38 ·· 5610G>T L1870F COR 
38 ·· 5620G>T E1874X COR 
39 rs77428810 5822G>A R1941H MAPKKK 
41 ·· 6016T>C Y2006H MAPKKK 
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41 rs34015634 6035T>C I2012T MAPKKK 
41 rs34637584 6055G>A G2019S MAPKKK 
41 rs35870237 6059T>C I2020T MAPKKK 
41 rs78029637 6091A>T T2031S MAPKKK 
42 rs111739194 6187delCTCTA L2063X MAPKKK 
42 rs33995883 6241A>G N2081D MAPKKK 
43 rs10878405 6324G>A E2108E MAPKKK 
43 rs12423862 6356C>T P2119L MAPKKK 
44 rs111691891 6422C>T T2141M ·· 
44 rs34869625 6510C>A G2170G WD40 
44 rs35658131 6566A>G Y2189C WD40 
46 rs12581902 6782A>T N2261I WD40 
48 rs113511708 7067C>T T2356I WD40 
48 rs34778348 7153G>A G2385R WD40 
48 rs33962975 7155A>G G2385G WD40 
48 rs79546190 7168G>A V2390M WD40 
49 rs78964014 7183G>A E2395K WD40 
49 rs111272009 7187insGT T2356fsX2360 WD40 
49 rs3761863 7190C>T M2397T WD40 
49 rs60545352 7224G>A M2408I WD40 
50 ·· 7397T>A L2466H WD40 





서론: LRRK2 유 자는 염색체 12p12 에 치하며, 상염색체 우성 
유  양식을 보이는 가족성 킨슨병을 일으키는 원인 유 자 의 
하나이다. 인종에 따라 유  변이의 분포가 상이함을 고려하면 다른 
인종을 상으로 한 LRRK2 유 자의 유  변이 연구 결과를 한국
인에게 그 로 용하는 것은 하지 못한다. 한국인을 상으로 
한 연구는 LRRK2 유 자  극히 일부 유  변이들에 한 킨
슨병의 감수성만 연구되었다. 따라서 한국인을 상으로 LRRK2 유
자의 122 개 유  변이를 분석하여 각 유  변이가 가지는 킨
슨병에 한 감수성에 한 분석이 필요하다.  
방법: 한국인의 산발성 킨슨병 663 명, 환자와 연 계가 아닌 정
상인 406 명으로 총 1069 명을 상으로 하 다. 122 개의 LRRK2 엑
손 변이에 한 단일염기다형성 분석을 하 고, 이들  다형성이 
있는 엑손 변이를 선별하 다. 카이제곱검정으로 환자군과 조군의 
빈도가 유의한 차이를 보이는 엑손 변이를 선별한 후， 로지스틱 
회귀분석으로 통하여 각 엑손 변이형이 가지는 킨슨병의 발병 
험도에 한 오즈비를 도출하 다.  
결과: 다  검정에 한 본페로니 수정으로 도출한 유의수
(p=0.002) 으로 검정하 을 때, 통계 으로 유의한 결과를 보
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인 엑손 변이는 없었다. 하지만 LRRK2 p.N551K (rs7308720; OR 
0.69, 95% CI 0.52-0.92; p=0.012), p.R1398H (rs7133914; OR 0.68, 
95% CI 0.51-0.91; p=0.009), p.K1423K (rs11175964; OR 0.69, 95% 
CI 0.52-0.93; p=0.014), p.M2397T (rs3761863; OR 0.73, 95% CI 
0.56-0.95; p=0.020) 엑손 변이 보인군에서 그 지 않은 군에 비하
여 낮은 험도를 보 고， LRRK2 p.A419V (rs34594498; OR 2.21, 
95% CI 1.11-4.38; p=0.023) 보인군은 그 지 않은 군에 비하여 높
은 험도를 보 다. 연  불균형 분석 (linkage disequilibrium 
analysis) 결과 p.N551K, p.R1398H, p.K1423K 의 세가지 엑손 변이
가 강한 연  불균형 (r2>0.8) 을 보 다. 
결론: 한국인을 상으로 한 122 개 LRRK2 엑손 변이 분석 결과 
통계 으로 유의하게 킨슨병의 발병 험도를 높이는 LRRK2 
엑손 변이는 없었다. 하지만 이러한 연구 결과의 원인은 LRRK2 엑
손 변이와 킨슨병 간의 연 성이 없어서라기 보다는 연구 상의 
수가 부족하여 통계 으로 유의한 결과를 도출하지 못하 을 가능
성이 크므로, 충분한 수의 환자, 정상인을 상으로 한 연구가 필요
하다. 
------------------------------------- 
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